Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Novavax

Concerns about the omicron variant as well as some good news are helping drive these vaccine stocks higher.

Why BioNTech, Moderna, and Novavax Stocks Are Jumping Today

The shares of Moderna Inc (NASDAQ: MRNA) have received a price target of $348 from Piper Sandler. These are the details.

Moderna Stock (MRNA): $348 Price Target From Piper Sandler

Seagen

Vertex Pharmaceuticals

These stocks could be just what you need to put in your stocking.

3 Biotech Stocks That Could Make You Richer in December (and Beyond)

AstraZeneca

Johnson & Johnson

Pfizer

It depends on what data the FDA requires.

How Quickly Could Vaccines Targeting the Omicron Variant Be Available?

It looks like the winners will keep winning.

What Does the Omicron Variant Mean for Vaccine Stocks?

Moderna Inc. (NASDAQ: MRNA) is a biotech firm that focuses on mRNA vaccines and therapeutics. The company announced the results of the mRNA-1010 flu vaccine candidate.

Moderna drops 25% as its MRNA flu vaccine's phase 1 data

The answer depends on some key assumptions.

How Will the Omicron Variant Impact Moderna Stock?

Moderna Inc (NASDAQ: MRNA) shares are trading lower Friday after the company announced interim Phase 1 data for its mRNA flu vaccine. Moderna said mRNA-1010 successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination for all doses tested in younger and older adults in the study.

Here's Why Moderna May Be Ready To Head Higher Again

Despite crashing nearly 50% since August, Moderna is still the third best-performing stock in the S&P 500 this year.

Moderna Stock Crash Has Wiped Nearly $100 Billion As Flu Vaccine Results Trigger Latest Plunge

Moderna Inc (NASDAQ: MRNA) says that it's on its way to having two mRNA vaccines against different seasonal flu viruses. The Company released the first early data from Phase 1 study of mRNA-1010, announcing that all doses of the shot significantly boosted antibodies in younger and older adults without "significant safety findings.

Moderna Posts Data From Early mRNA Flu Vaccine Study, Pivotal Trial On Its Way

Moderna Inc. MRNA, -3.95% announced new supply agreements for COVID-19 vaccine doses with Gavi, the vaccine alliance, that includes 20 million additional doses this year and 20 million more doses next year. The biotechnology company said it will supply 20 million vaccine doses to Covax, a United Nations program that aims to deliver vaccines to lower-income countries, to boost the total supply made available to Covax in 2021 to 54 million doses.

Moderna boosts supply agreements with Covax, Gavi by 20 million doses this year and 20 million doses next year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022

Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022

Moderna Inc. MRNA, -3.95% announced Friday interim data from a Phase 1 study of its flu vaccine candidate, mRNA-1010, which showed that mRNA-1010 successfully boosted titers against all strains 29 days after vaccination, at all doses tested in both younger and older adults. "It is encouraging to see that participants in the study who received the 50 ug dose, including older adults, achieved robust increases in geometric mean antibody titers against H1N1 and H3N2, the strains responsible for the vast majority of morbidity and mortality in this age group," said Chief Executive Stéphane Bancel.

Moderna's flu vaccine candidate shows positive interim results in Phase 1 study

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update

Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update

Moderna's cash growth will continue as demand for booster shots and vaccines for the omicron variant increase, giving a boost to MRNA stock. The post Why You Should Buy Moderna Stock at Every Dip appeared first on InvestorPlace.

Why You Should Buy Moderna Stock at Every Dip

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10

Moderna to Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10

Inari Medical

Our Foolish roundtable has three stocks to invest in as we enter our third year of the COVID pandemic.

3 COVID-19 Stocks That Should Beat the Market in 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Launches AI Academy in Partnership with Carnegie Mellon University

Moderna Launches AI Academy in Partnership with Carnegie Mellon University

Artificial intelligence-run fund AMOM also loaded up on shares of Netflix, and bet big on a very low-profile medical device specialist.

Moderna Stock Is Sold by This Robot Trader. It Bought Tesla and Merck Instead.

A British study evaluating mixing COVID-19 vaccines showed a better immune response in people after the first dose of AstraZeneca Plc (NASDAQ: AZN) or Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) shots followed by Moderna Inc's (NASDAQ: MRNA) nine weeks later. AstraZeneca-Oxford vaccine followed by a Moderna or Novavax Inc (NASDAQ: NVAX) shot showed higher antibodies and T-cell responses versus two doses of AstraZeneca-Oxford.

Mix & Match Pfizer, AstraZeneca COVID-19 Vaccine With Moderna Shows Improved Immune Response

Merck

Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.

Vaccine Stocks Down as Omicron May Not Be Too Severe

The stock price of Moderna Inc (NASDAQ: MRNA) fell by 13.49% today. This is why it happened.

Moderna Stock (MRNA): Why The Price Dropped Today

Dr. Fauci has implied that the omicron variant may not be as severe as feared. Vaccine stocks have taken a hit as a result.

Vaccine Stocks: Why MRNA, BNTX, NVAX, PFE Stocks Are Stumbling Today

Investors are bailing out of vaccine stocks. But should they be selling?

Why Moderna Stock Crashed Today

Moderna Inc (NASDAQ:MRNA) shares are pulling back among other vaccine stocks due to COVID-19 omicron variant concerns as well as cooling off from a good November. The World Health Organization is now saying the omicron variant has been detected in more than 40 countries since it was first reported by South African health authorities.

News for Moderna Stock (MRNA)